Trial suggests KaNDy’s menopause drug could be better than HRT

Trial suggests KaNDy’s menopause drug could be better than HRT

New women’s health biotech KaNDy Therapeutics—rumored to have attracted buyout interest from Allergan—has just reported data on its lead product that could enhance its allure.

This content was originally published here.

Recommended For You

subscribe to our newsletter

let's subscribe!

Newsletter